NASDAQ OMX

InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC

Dela

InSphero AG / InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

New 3D InSight(TM) Human Liver Fibrosis Model represents a powerful tool for screening efficacy and safety of anti-fibrotic drugs in vitro.

Schlieren, Switzerland, Oct. 18, 2017 (GLOBE NEWSWIRE) -- InSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, will present data characterizing and demonstrating the utility of its new 3D InSight(TM) Human Liver Fibrosis Model for screening efficacy of anti-fibrotic drugs.  The findings will be presented at oral and poster presentations this Friday at the annual meeting of the American Association for the Study of Liver Disease (AASLD) Conference in Washington, DC. 

Anti-fibrotic therapies aim to inhibit activation of hepatic stellate cell (HSCs), thereby preventing excessive accumulation of extracellular matrix (ECM) proteins, such as collagen, which can lead to cirrhosis and liver failure.  The InSphero 3D InSight(TM) Human Liver Fibrosis Model is unique in that it contains all liver cell types necessary to mimic fibrosis in vitro in a high throughput, screening-compatible platform.  

InSphero Chief Scientific Officer Dr. Patrick Guye says, "Our 3D human fibrosis model is composed of primary human liver cells, including HSCs, hepatocytes, Kupffer cells, and liver endothelial cells, all of which are required to accurately reflect the clinical fibrotic disease state in a cell culture model. Treatment of the model with TGF-b1, a known inducer of HSC activation, was shown to trigger strong induction of pro-fibrotic gene expression and ECM protein accumulation in the microtissue, resulting in collagen deposition and diminished hepatocyte function, both hallmarks of liver fibrosis. Even more promising, we were clearly able to demonstrate successful inhibition of disease progression on a phenotypic and transcriptional level using drugs known to interfere with pro-fibrotic signalling pathways." 

Dr. Jan Lichtenberg, InSphero Chief Executive Officer and Co-founder, notes, "These findings support the power of our model to help drug discovery groups meet the demand for safer, more effective anti-fibrotic drugs. The initial feedback from beta testers within major pharmaceutical groups with fibrosis programs has been overwhelmingly positive.  Not only does the model overcome the lack of cellular complexity of current in vitro models, but being based on our pharma-validated Human Liver Microtissue platform, it can deliver valuable data on both the efficacy and safety of drug candidates, without the use of animal models."  

AASLD Presentation Details
Friday, October 20: 12:00 - 1:30 PM
Abstract #385: Development and characterization of a novel in vitro human liver fibrosis model for efficacy testing of anti-fibrotic drugs based on 3D Human Liver Microtissues
Poster presented by: Dr. Radina Kostadinova, InSphero AG

For more information about InSphero, visit www.insphero.com.

###

InSphero contacts 

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
randy.strube@insphero.com

Dr. Jan Lichtenberg
Chief Executive Officer and Co-founder
Phone +41 44 5150490
jan.lichtenberg@insphero.com

About InSphero

InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight(TM) Microtissues and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreas, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology. All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized platform, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and onsite training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models.

InSphero 3D InSight(TM) solutions drive significant findings in peer-reviewed journals, through collaborative industry initiatives such as EU-ToxRisk and HeCaToS, and have gained validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies.

Founded in 2009, the privately held company is headquartered in Switzerland, with subsidiaries in the United States and Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and LinkedIn.

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1201e5f9-a462-4dca-b453-e61881c14090

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/63584ccd-618f-48fd-aec4-5e289e46c2de

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c0354196-0927-49f8-9fb5-2a57e0e2d025

Randy Strube
InSphero AG
800-619-6800
randy.strube@insphero.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: InSphero AG via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

BIMobject AB: Kallelse till extra bolagsstämma den 5 september 2018. Patrick Söderlund och Hjalmar Winbladh föreslås som nya styrelseledamöter i BIMobject AB. Split 2:1 föreslås.15.8.2018 15:30Pressmeddelande

Aktieägare representerande cirka 49 procent av rösterna i BIMobject AB har meddelat att de föreslår att Hjalmar Winbladh och Patrick Söderlund väljs till nya styrelseledamöter vid en extra bolagsstämma onsdagen den 5 september 2018. Ben O'Donnell lämnar sitt uppdrag som styrelseledamot i samband med den extra bolagsstämman. Styrelsen kommer därefter att bestå av Stefan Larsson (VD), Anders Wilhjelm (ordförande), Johannes Reischböck, Philippe Butty, Hjalmar Winbladh och Patrick Söderlund. Vidare föreslås ändrad ersättning till styrelsen. Nytt arvode utgår med 800 000 kronor, fördelat mellan styrelseordförande och Söderlund om 400 000 kronor vardera. Styrelsen föreslår även att stämman beslutar om aktieuppdelning av befintliga utestående aktier i förhållande 2:1. Patrick Söderlund, född 1973 och svensk medborgare, är Chief Design Officer samt Executive Vice President på Electronic Arts. I denna roll leder han utvecklingen av bolagets tekniska innovationer och bolagets marknadsföringsteam

BIMobject AB: Notice to attend Extraordinary General Meeting on September 5, 2018. Patrick Söderlund and Hjalmar Winbladh proposed as new Board Members in BIMobject AB. A split 2:1 is proposed.15.8.2018 15:30Pressmeddelande

Shareholders representing approximately 49 percent of the votes in BIMobject AB have announced that they propose that Hjalmar Winbladh and Patrick Söderlund are appointed new Board Members at an Extraordinary General Meeting to be held on Wednesday September 5, 2018. Ben O'Donnell resigns as Board Member in connection with the Extraordinary General Meeting. The Board will thereafter be composed of Stefan Larsson (CEO), Anders Wilhjelm (Chairman), Johannes Reischböck, Philippe Butty, Hjalmar Winbladh and Patrick Söderlund. Furthermore, a change in remuneration to the Board is proposed. The new Board fee totals SEK 800,000 and is to be divided between the Chairman and Söderlund with SEK 400,000 each. The board also proposes that the General Meeting resolves to split the company's shares 2:1. Patrick Söderlund, born in 1973 and a Swedish citizen, is Chief Design Officer and Executive Vice President at Electronic Arts. In his present role he manages the development of technology innovation

BIMobject AB: Offentliggörande av delårsrapport april - juni 201815.8.2018 08:00Pressmeddelande

Den fullständiga rapporten finns även tillgänglig på bolagets hemsida (info.bimobject.com). Andra kvartalet 2018 Faktureringen ökade med 83 procent och uppgick till 33 MSEK (18). Koncernens nettoomsättning ökade med 75 procent och uppgick till 28 MSEK (16). Fördelning mellan projekt och webservices (prenumerationer) var 40/60 procent (60/40). Bruttomarginalen ökade till 86 procent (81). Koncernens rörelseresultat förbättrades och uppgick till -15 MSEK (-17). Resultat per aktie uppgick till -0,29 SEK (-0,31) före utspädning. Kassaflödet från löpande verksamheten uppgick till -18 MSEK (-15). Ackumulerat antal användare ökade och uppgick till cirka 845 000. Ackumulerat antal nedladdningar uppgick till 25,5 miljoner. Antalet tillverkare uppgick till 1230. Styrelsen beslutade att påbörja processen för notering av bolaget vid Nasdaq Stockholm. Viktiga händelser andra kvartalet BIMobject ingår samarbete med Pipe Retail Solution för att effektivisera digital butiksplanering. BIMobject tecknar

BIMobject AB: Interim Report April - June 201815.8.2018 08:00Pressmeddelande

Second quarter 2018 Billing increased by 83 percent to SEK 33 (18) million. The Group's net sales increased by 75 percent to SEK 28 (16) million. The distribution between projects and web services (subscriptions) was 40/60 (60/40) percent. The gross margin increased to 86 (81) percent. The Group's operating profit improved to SEK -15 (-17) million. Basic earnings per share amounted to SEK -0.29 (-0.31). Cash flow from operating activities was SEK -18 (-15) million. The accumulated number of users increased to approximately 845,000. The accumulated number of downloads amounted to 25.5 million. The number of manufacturers was 1,230. The Board decided to initiate the process of listing the Company on Nasdaq Stockholm. Significant events during the second quarter BIMobject forms strategic partnership with Pipe Retail Solution to streamline digital planning of retail spaces. BIMobject signs Letter of Intent with leading US 3D media company Matterport. CEO's comments EQT Ventures' investment

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress13.8.2018 08:00Pressmeddelande

Press Release 13 August 2018 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress Immunicum AB (publ; IMMU.ST) announced today that the company will present a poster on its lead development candidate, ilixadencel, at the European Society for Medical Oncology (ESMO) 2018 Congress, held October 19-23, 2018 in Munich, Germany. Immunicum will announce the complete data through a press release following the presentation. The poster abstract will also be published in the ESMO 2018 Congress Abstract Book, a supplement to the official ESMO journal, Annals of Oncology. Poster Information: Title: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect Presentation Number: 440P Presenter: Dr. Alex Karlsson-Parra, Chief Scientific Officer Date & Time: Monday, October 22, 2018; 12.45 - 13.45 CET Location: H

Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress13.8.2018 08:00Pressmeddelande

Pressmeddelande 13 augusti 2018 Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress Immunicum AB (publ; IMMU.ST) tillkännagav idag att bolaget kommer att presentera en poster om sin ledande produktkandidat, ilixadencel, på 2018 års kongress för European Society for Medical Oncology (ESMO) , som hålls den 19-23 oktober 2018 i München i Tyskland. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande som följer efter presentationen. En sammanfattning av postern kommer också att publiceras i ESMO 2018 Congress Abstract Book, ett komplement till ESMO:s officiella årsbok, Annals of Oncology. Posterinformation: Titel: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect (Intratumoral administration av pro-inflammatoriska allogena dendritiska celler som kan lagr

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum